PE20141659A1 - Dominios variables singulares anti-vgf fusionados con dominios de fc - Google Patents
Dominios variables singulares anti-vgf fusionados con dominios de fcInfo
- Publication number
- PE20141659A1 PE20141659A1 PE2014000126A PE2014000126A PE20141659A1 PE 20141659 A1 PE20141659 A1 PE 20141659A1 PE 2014000126 A PE2014000126 A PE 2014000126A PE 2014000126 A PE2014000126 A PE 2014000126A PE 20141659 A1 PE20141659 A1 PE 20141659A1
- Authority
- PE
- Peru
- Prior art keywords
- dab
- region
- domains
- seq
- vgf
- Prior art date
Links
- 238000010276 construction Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000006444 vascular growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA CONSTRUCCION DE UNION A ANTIGENO QUE COMPRENDE: DOS ANTICUERPOS DE DOMINIO (dAbs) SEPARADOS POR UNA REGION Fc DE UNA SOLA CADENA DE ANTICUERPO, EN DONDE CADA dAb ES CAPAZ DE UNIRSE AL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF), EN DONDE UN dAb ESTA UNIDO AL EXTREMO N DE LA REGION Fc, EL CUAL ES UN dAb DE CADENA PESADA QUE COMPRENDE UNA O MAS SECUENCIAS DE CDR DE SEQ ID NO: 114, 115 Y 116, Y EL OTRO dAb ESTA UNIDO AL EXTREMO C DE LA REGION Fc, EL CUAL ES UN dAb DE CADENA LIGERA KAPPA O LAMBDA QUE COMPRENDE UNA O MAS SECUENCIAS DE CDR DE SEQ ID NO: 117, 118 Y 119. LA REGION Fc ES LA SECUENCIA DE IgG1 DE SEQ ID NO: 110. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, UNA CELULA HOSPEDERA Y UN METODO PARA LA PRODUCCION DE UNA CONSTRUCCION DE UNION DE ANTIGENO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512138P | 2011-07-27 | 2011-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141659A1 true PE20141659A1 (es) | 2014-11-21 |
Family
ID=46579044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000126A PE20141659A1 (es) | 2011-07-27 | 2012-07-25 | Dominios variables singulares anti-vgf fusionados con dominios de fc |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9499612B2 (es) |
| EP (1) | EP2736925A2 (es) |
| JP (1) | JP5987057B2 (es) |
| KR (1) | KR101632620B1 (es) |
| CN (1) | CN103842380A (es) |
| AU (1) | AU2012288846B2 (es) |
| BR (1) | BR112014001855A2 (es) |
| CA (1) | CA2842099A1 (es) |
| CL (1) | CL2014000204A1 (es) |
| CO (1) | CO7020847A2 (es) |
| CR (1) | CR20140047A (es) |
| DO (1) | DOP2014000017A (es) |
| EA (1) | EA028886B1 (es) |
| HK (1) | HK1198446A1 (es) |
| MA (1) | MA35352B1 (es) |
| MX (1) | MX2014001019A (es) |
| PE (1) | PE20141659A1 (es) |
| PH (1) | PH12014500220A1 (es) |
| WO (1) | WO2013014208A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2960297A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2016231122A1 (en) | 2015-03-11 | 2017-09-07 | Glaxosmithkline Intellectual Property Development Limited | TSLP binding proteins |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3429624A4 (en) * | 2016-03-16 | 2020-04-22 | The Regents of The University of California | PROTEIN A BINDING POLYPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE THEREOF |
| JP2019510786A (ja) | 2016-04-05 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 免疫療法におけるＴＧＦβの阻害 |
| JP2020514301A (ja) * | 2017-01-06 | 2020-05-21 | モメンタ ファーマシューティカルズ インコーポレイテッド | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
| CN109021103B (zh) * | 2017-06-12 | 2022-08-23 | 上海睿智化学研究有限公司 | 抗人血管内皮生长因子的抗体及其制备方法和应用 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| EP4294839A1 (en) * | 2021-02-19 | 2023-12-27 | DotBio Pte. Ltd. | Vegfa-binding molecules |
| US20240335562A1 (en) * | 2021-08-04 | 2024-10-10 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| JP2024529119A (ja) * | 2021-08-13 | 2024-08-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 |
| KR102764987B1 (ko) * | 2022-08-02 | 2025-02-12 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
| EP4574846A1 (en) * | 2022-09-14 | 2025-06-25 | Quaerite Biopharm Research (Beijing) Co., Ltd. | Anti-vegfa fusion protein, and preparation method therefor and use thereof |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| ATE380865T1 (de) | 1998-05-13 | 2007-12-15 | Domantis Ltd | Phagen-display-selektionssystem für korrekt gefaltete proteine |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| IL127127A0 (en) * | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| JP2003523742A (ja) | 2000-02-03 | 2003-08-12 | ドマンティス リミテッド | コンビナトリアルタンパク質ドメイン |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CN101039959A (zh) * | 2004-06-30 | 2007-09-19 | 杜门蒂斯有限公司 | 用于治疗炎性疾病的组合物和方法 |
| CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| AU2006270718B2 (en) | 2005-07-22 | 2011-07-21 | Kyowa Kirin Co., Ltd. | Genetically modified antibody composition |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| DE112008003232T5 (de) | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| CA2707986A1 (en) * | 2007-12-13 | 2009-06-18 | Glaxo Group Limited | Compositions for pulmonary delivery |
| PT2235064E (pt) * | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| EP2401298A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| CN102458471A (zh) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| EP2504360B1 (en) * | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| EP2670778A1 (en) * | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
-
2012
- 2012-07-25 MX MX2014001019A patent/MX2014001019A/es unknown
- 2012-07-25 PH PH1/2014/500220A patent/PH12014500220A1/en unknown
- 2012-07-25 CN CN201280047197.3A patent/CN103842380A/zh active Pending
- 2012-07-25 CA CA2842099A patent/CA2842099A1/en not_active Abandoned
- 2012-07-25 KR KR1020147005082A patent/KR101632620B1/ko not_active Expired - Fee Related
- 2012-07-25 PE PE2014000126A patent/PE20141659A1/es not_active Application Discontinuation
- 2012-07-25 EP EP12738476.6A patent/EP2736925A2/en not_active Ceased
- 2012-07-25 WO PCT/EP2012/064632 patent/WO2013014208A2/en not_active Ceased
- 2012-07-25 EA EA201391812A patent/EA028886B1/ru not_active IP Right Cessation
- 2012-07-25 AU AU2012288846A patent/AU2012288846B2/en not_active Ceased
- 2012-07-25 HK HK14111941.1A patent/HK1198446A1/xx unknown
- 2012-07-25 JP JP2014522089A patent/JP5987057B2/ja not_active Expired - Fee Related
- 2012-07-25 US US14/235,330 patent/US9499612B2/en not_active Expired - Fee Related
- 2012-07-25 BR BR112014001855A patent/BR112014001855A2/pt not_active IP Right Cessation
-
2014
- 2014-01-27 CL CL2014000204A patent/CL2014000204A1/es unknown
- 2014-01-27 DO DO2014000017A patent/DOP2014000017A/es unknown
- 2014-01-28 CR CR20140047A patent/CR20140047A/es unknown
- 2014-01-29 CO CO14018316A patent/CO7020847A2/es unknown
- 2014-02-18 MA MA36759A patent/MA35352B1/fr unknown
-
2016
- 2016-10-14 US US15/294,058 patent/US20170029494A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA35352B1 (fr) | 2014-08-01 |
| CA2842099A1 (en) | 2013-01-31 |
| US20140205604A1 (en) | 2014-07-24 |
| KR101632620B1 (ko) | 2016-06-23 |
| EP2736925A2 (en) | 2014-06-04 |
| WO2013014208A3 (en) | 2013-05-10 |
| EA028886B1 (ru) | 2018-01-31 |
| EA201391812A1 (ru) | 2014-06-30 |
| AU2012288846A1 (en) | 2014-02-06 |
| JP5987057B2 (ja) | 2016-09-06 |
| CL2014000204A1 (es) | 2014-07-25 |
| CN103842380A (zh) | 2014-06-04 |
| JP2014523746A (ja) | 2014-09-18 |
| DOP2014000017A (es) | 2014-04-30 |
| KR20140041908A (ko) | 2014-04-04 |
| MX2014001019A (es) | 2014-05-13 |
| CR20140047A (es) | 2014-03-24 |
| US20170029494A1 (en) | 2017-02-02 |
| US9499612B2 (en) | 2016-11-22 |
| AU2012288846B2 (en) | 2016-05-19 |
| PH12014500220A1 (en) | 2019-03-22 |
| CO7020847A2 (es) | 2014-08-11 |
| WO2013014208A2 (en) | 2013-01-31 |
| BR112014001855A2 (pt) | 2017-02-21 |
| HK1198446A1 (en) | 2015-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
| AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| GT201300149A (es) | Proteinas de union al tnf-a | |
| AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| GT201400045A (es) | Anticuerpo anti-abtcr | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| CR20210429A (es) | ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562) | |
| EA201890028A1 (ru) | Антитело, связывающее cd3 человека | |
| PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos | |
| MX387324B (es) | Variantes de regiones fc de igg1 de humano y usos de las mismas. | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| EA201300978A1 (ru) | Антитела к сеа | |
| PE20150222A1 (es) | Anticuerpos multiespecificos | |
| PE20081478A1 (es) | Anticuerpos cd44 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |